A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

Rees Lesley, Tizard E. Jane, AJ Morgan, Cubitt W. David, S Finerty, Oyewole-Eletu Tintilade A., Owen Karen, Royed Collin, Stevens Servi J., Schroff Rushana C., Tanday Manjit K., AD Wilson, Middeldorp Jaap M., Amlot Peter L., Steven Neil M.

Research output: Contribution to journalArticle (Academic Journal)peer-review

73 Citations (Scopus)

Abstract

Vaccination against Epstein-Barr virus (EBV), inducing an antibody response to the envelope glycoprotein gp350,might protect EBV-negative children with chronic kidney disease from lymphoproliferative disease after transplantation. A phase I trial recruited children with chronic kidney disease to two successive cohorts given three injections of 12.5 µg (n=6) and 25 µg (n=10) recombinant gp350/alhydrogel vaccine more than 6 to 8 weeks. One in each cohort acquired wild EBV before the week 28 evaluation. Both doses were similarly immunogenic, inducing an IgG response in all 13 evaluable patients. Neutralizing antibodies were detected in four recipients (1/4 in the 12.5µg and 3/9 in the 25 µg cohort). Median time from first vaccination to transplantation was 24 weeks. Immune responses declined rapidly and were unlikely to affect posttransplant events. The vaccine was immunogenic but prolonged vaccination to time of transplantation, or improved adjuvants are required in future trials to reduce posttransplant EBV load and risk of lymphoproliferative disease.
Translated title of the contributionA Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation
Original languageEnglish
Pages (from-to)1025 - 1029
Number of pages5
JournalTransplantation
Volume88
Issue number8
DOIs
Publication statusPublished - Oct 2009

Bibliographical note

Publisher: Lippincott Williams & Wilkins

Fingerprint Dive into the research topics of 'A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation'. Together they form a unique fingerprint.

Cite this